Compare ACADIA Pharmaceuticals Inc. (ACAD) vs SiTime Corporation (SITM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs SiTime Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $26.2 (market cap $4.49B), while SiTime Corporation trades at $590.04 (market cap $17.74B). The key difference: SiTime Corporation is far larger — about 4× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals.
| ACAD | SITM | |
|---|---|---|
Market Cap | $4.49B | $17.74B |
Sector | Health | Technology |
52-Week High | $28.06 | $901.60 |
52-Week Low | $20.06 | $190.16 |
Enterprise Value | $3.69B | $16.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
SITM trades at $615.46, up 2.29% today, showing strong momentum with three consecutive quarterly earnings beats. The stock faces technical headwinds with a bearish moving average signal, while fundamentals reveal robust revenue growth but negative profitability metrics. Recent news highlights the completed acquisition of Renesas' timing business and strong AI-driven demand, with management raising full-year growth guidance to at least 80%.
The outlook remains promising due to accelerating AI infrastructure demand and strategic acquisitions, though investors face risks from negative profit margins and high valuation multiples. Analyst consensus is unanimously bullish with a $743.75 price target representing 21% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
